

20 March 2024 EMA/HMPC/320292/2023 Committee on Herbal Medicinal Products (HMPC)

# European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum

Draft - Revision 1

| Initial assessment   |                            |
|--|----------------------------|
| Discussion in Working Party on European Union monographs and   | May 2012                   |
| European Union list (MLWP)   | September 2012             |
|  | November 2012              |
|  | March 2013                 |
| Adopted by Committee on Herbal Medicinal Products (HMPC) for   | 14 May 2013                |
| release for consultation   | 14 May 2013                |
| End of consultation (deadline for comments)  | 15 November 2013           |
| Rediscussion in MLWP   | January 2014               |
| Adoption by HMPC   |                            |
| Monograph (EMA/HMPC/307781/2012)   |                            |
| Assessment Report (EMA/HMPC/307782/2012)   |                            |
| List of References (EMA/HMPC/307783/2012)  | 25 March 2014              |
| Overview of Comments received during the public consultation   |                            |
| (EMA/HMPC/32373/2014)  |                            |
| HMPC Opinion (EMA/HMPC/283230/2014)  |                            |
| First systematic review  |                            |
| Discussion in MLWP   | July 2023                  |
|  | January 2024<br>March 2024 |
|  | March 2024                 |
| Adopted by HMPC for release for consultation   | 20 March 2024              |
| Start of public consultation   | 15 April 2024              |
| End of consultation (deadline for comments). Comments should be provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u> | 15 July 2024               |

| Keywords | Committee on Herbal Medicinal Products; HMPC; European Union herbal         |
|----------|---|
|          | monographs; herbal medicinal products; traditional use; Eucalyptus globulus |
|          | Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker,  |
|          | aetheroleum; Eucalypti aetheroleum; Eucalyptus oil                          |

 Official address
 Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

 Address for visits and deliveries
 Refer to www.ema.europa.eu/how-to-find-us

 Send us a question
 Go to www.ema.europa.eu/contact

 Telephone +31 (0)88 781 6000
 An agency of the European Union



 $\odot$  European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.

| BG (bălgarski): Евкалиптово масло                | LT (lietuvių kalba): Eukaliptų eterinis aliejus |
|--|---|
| CS (čeština): blahovičníková silice              | LV (latviešu valoda): Eikalipta ēteriskā eļļa   |
| DA (dansk): Eucalyptusolie                       | MT (malti): Żejt tal-Ewkaliptus                 |
| DE (Deutsch): Eukalyptusöl                       | NL (nederlands): Eucalyptusolie                 |
| EL (elliniká): αιθέριο έλαιο ευκαλύπτου          | PL (polski): Olejek eteryczny eukaliptusowy     |
| EN (English): Eucalyptus oil                     | PT (português): Óleo essencial de eucalipto     |
| ES (espanol): Eucalipto, aceite esentcial de     | RO (română): ueli volatil de eucalipt           |
| ET (eesti keel): eukalüptiõli                    | SK (slovenčina): Eukalyptovà silica             |
| FI (suomi): eukalyptusöljy                       | SL (slovenščina): eterično olje evkalipta       |
| FR (français): Eucalyptus (huile essentielle d') | SV (svenska): Eukalyptusolja                    |
| HU (magyar): Eukaliptuszolaj                     | IS (íslenska):                                  |
| HR (hrvatska): Eukaliptusovo eterično ulje       | NO (norsk): Eukalyptusolje                      |
| IT (italiano): Eucalipto essenza                 |   |

## European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum

## 1. Name of the medicinal product

To be specified for the individual finished product.

## 2. Qualitative and quantitative composition<sup>1, 2</sup>

| Well-established use | Traditional use  |
|----------------------|--|
|                      | With regard to the registration application of<br>Article 16d(1) of Directive 2001/83/EC   |
|                      | <i>Eucalyptus globulus</i> Labill.; <i>Eucalyptus polybractea</i> R.T. Baker; <i>Eucalyptus smithii</i> R.T. Baker, aetheroleum (Eucalyptus oil) |
|                      | i) Herbal substance<br>Not applicable  |
|                      | ii) Herbal preparations<br>Essential oil   |

#### 3. Pharmaceutical form

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Herbal preparations in solid dosage forms for oral use.                                       |
|                      | Herbal preparations in liquid dosage forms for inhalation, cutaneous use and bath additive.   |
|                      | Herbal preparations in semi-solid dosage forms for cutaneous use.                             |
|                      | The pharmaceutical form should be described by the European Pharmacopoeia full standard term. |

 $<sup>^1</sup>$  The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

<sup>&</sup>lt;sup>2</sup> The material complies with the Ph. Eur. monograph (ref.: 07/2021:0390)

European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum EMA/HMPC/320292/2023

# 4. Clinical particulars

## 4.1. Therapeutic indications

| Well-established use | Traditional use  |
|----------------------|--|
|                      | Indication 1)  |
|                      | Traditional herbal medicinal product used for relief of cough associated with cold.  |
|                      | Indication 2)  |
|                      | Traditional herbal medicinal product used for the symptomatic relief of localised muscle pain.                                   |
|                      | The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. |

#### 4.2. Posology and method of administration

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Posology  |
|                      | Indication 1)   |
|                      | <u>Oral use</u><br>Adolescents, adults and elderly  |
|                      | Single dose: 100-200 mg, 2-5 times daily<br>Daily dose: 200-600 mg  |
|                      | The use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindication').<br>The use in children between 2 and 12 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use'). |
|                      | <u>Cutaneous use</u> <ul> <li>liquid dosage forms (pure eucalyptus oil)</li> </ul>  |
|                      | <i>Children from 3 years of age, adolescents, adults and elderly</i>  |
|                      | Single dose: rub a few drops on chest and back, 2-3 times daily   |
|                      | <ul> <li>semi-solid dosage forms (10% eucalyptus<br/>oil)</li> </ul>  |
|                      | Adolescents, adults and elderly and children between 3 and 12 years of age  |

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Single dose: apply a thin layer on chest and back, 2-3 times daily  |
|                      | The use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindication').<br>The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').  |
|                      | Inhalation <ul> <li>liquid dosage forms (pure eucalyptus oil)</li> </ul>  |
|                      | Adolescents, adults and elderly   |
|                      | Single dose: 3-8 drops per 250 ml boiling water,<br>3 times daily   |
|                      | Children between 3 and 11 years of age  |
|                      | Single dose: up to 2-4 drops per 250 ml boiling water, 3 times daily.   |
|                      | The use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').<br>The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use'). |
|                      | Bath additive<br>• liquid dosage forms  |
|                      | Adolescents, adults and elderly<br>Single dose: 1.5-6 g essential oil/100 l water, 3<br>to 4 times a week   |
|                      | Children between 3 and 11 years of age<br>Single dose: 0.5-3 g essential oil/100 l water, 3<br>to 4 times a week  |
|                      | Recommended bath temperature is 35-38°C, 10-20 min  |
|                      | The use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').<br>The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use'). |

| Indication 2)Cutaneous use• liquid dosage forms (pure eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the<br>affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10%<br>eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the<br>affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10%<br>eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: apply a thin layer on the affected<br>area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms |
|--|
| <ul> <li>liquid dosage forms (pure eucalyptus oil)</li> <li>Adolescents, adults and elderly and children between 3 and 12 years of age</li> <li>Single dose: rub a few drops on the skin of the affected area, 2-3 times daily</li> <li>in semi-solid dosage forms (ointments 10% eucalyptus oil)</li> <li>Adolescents, adults and elderly and children between 3 and 12 years of age</li> <li>Single dose: apply a thin layer on the affected area, 2 to 3 times daily</li> <li>The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').</li> <li>The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').</li> <li>Bath additive         <ul> <li>liquid dosage forms</li> </ul> </li> </ul>  |
| Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the<br>affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10%<br>eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: apply a thin layer on the affected<br>area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms  |
| between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the<br>affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10%<br>eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: apply a thin layer on the affected<br>area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms  |
| affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10%<br>eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: apply a thin layer on the affected<br>area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms  |
| eucalyptus oil)Adolescents, adults and elderly and children<br>between 3 and 12 years of ageSingle dose: apply a thin layer on the affected<br>area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms   |
| between 3 and 12 years of ageSingle dose: apply a thin layer on the affected<br>area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').<br>The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms  |
| area, 2 to 3 times dailyThe use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').Bath additive<br>• liquid dosage forms  |
| contraindicated (see section 4.3<br>'Contraindications').<br>The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').<br><u>Bath additive</u><br>• liquid dosage forms  |
| liquid dosage forms  |
|  |
| Adolescents, adults and elderly  |
| Single dose: 2.7-4 g essential oil/100 l water, 3 to 4 times a week  |
| Children between 3 and 12 years of age   |
| Single dose: 0.5-3 g essential oil/100 l water, 3 to 4 times a week  |
| Recommended bath temperature is 35-38°C,<br>10-20 min  |
| The use in children under 24 months of age is<br>contraindicated (see section 4.3<br>'Contraindications').<br>The use in children between 2 and 3 years of<br>age is not recommended (see section 4.4<br>'Special warnings and precautions for use').  |
| Duration of use  |
| Duration of use  |

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Indication 1)   |
|                      | If the symptoms persist longer than 1 week<br>during the use of the medicinal product, a<br>doctor or a qualified health care practitioner<br>should be consulted.                          |
|                      | Indication 2)   |
|                      | <u>Cutaneous use</u><br>If the symptoms persist longer than 2 weeks<br>during the use of the medicinal product, a<br>doctor or a qualified health care practitioner<br>should be consulted. |
|                      | Use as bath additive<br>If the symptoms persist longer than 1 week<br>during the use of the medicinal product, a<br>doctor or a qualified health care practitioner<br>should be consulted.  |
|                      | Method of administration  |
|                      | Oral use (indication 1)   |
|                      | Inhalation (indication 1)   |
|                      | Cutaneous use (indication 1 and 2)  |
|                      | Use as bath additive (indication 1 and 2)   |

## 4.3. Contraindications

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Hypersensitivity to eucalyptus oil or 1,8-cineol.   |
|                      | Children with history of seizures (febrile or not).   |
|                      | Children under 24 months of age, because there<br>is a risk that 1,8-cineole containing<br>preparations, like other essential oils, can induce<br>laryngospasm.                                       |
|                      | Full hot baths are contraindicated in cases of<br>large skin injuries and open wounds, acute skin<br>diseases, high fever, severe infections, severe<br>circulatory disturbances and cardiac failure. |

| Well-established use | Traditional use  |
|----------------------|--|
|                      | Indication 1   |
|                      | When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted.  |
|                      | If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.                          |
|                      | <u>Oral use</u><br>The use in children under 12 years of age has<br>not been established due to lack of adequate<br>data.                                      |
|                      | Eucalyptus oil should be used with caution in in inflamed and ulcerated conditions of the gastrointestinal tract.  |
|                      | <u>Inhalation</u><br>The use in children under 3 years of age has not<br>been established due to lack of adequate data.  |
|                      | Caution is necessary in inhalations with hot water, to avoid burns. The area of the eyes should be outside of the steam.                                       |
|                      | <u>Cutaneous use and use as bath additive</u><br>The use in children between 2 and 3 years of<br>age has not been established due to lack of<br>adequate data. |
|                      | Eye contact with unwashed hands after the application may potentially cause irritation.  |
|                      | Eucalyptus oil should not be applied on broken or irritated skin.  |
|                      | Indication 2   |
|                      | When reddening or swelling of the aching parts occur a doctor or a qualified health care practitioner should be consulted.                                     |
|                      | If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.                          |

## 4.4. Special warnings and precautions for use

| Well-established use | Traditional use   |
|----------------------|---|
|                      | The use in children between 2 and 3 years of age has not been established due to lack of adequate data. |
|                      | Eye contact with unwashed hands after the application may potentially cause irritation.                 |
|                      | Eucalyptus oil should not be applied on broken or irritated skin.                                       |

# **4.5.** Interactions with other medicinal products and other forms of interaction

| Well-established use | Traditional use |
|----------------------|-----------------|
|                      | None reported.  |

#### 4.6. Fertility, pregnancy and lactation

| Well-established use | Traditional use  |
|----------------------|--|
|                      | Safety during pregnancy and lactation has not<br>been established. In the absence of sufficient<br>data, the use during pregnancy and lactation is<br>not recommended.<br>No fertility data are available. |

#### 4.7. Effects on ability to drive and use machines

| Well-established use | Traditional use  |
|----------------------|--|
|                      | No studies on the effect on the ability to drive and use machines have been performed. |

#### 4.8. Undesirable effects

| Well-established use | Traditional use  |
|----------------------|--|
|                      | <u>All uses:</u><br>Immune system disorders<br>allergic reactions including severe allergic<br>reactions as systemic allergic reactions      |
|                      | <u>Oral use:</u><br>Gastrointestinal disorders<br>gastrointestinal reactions (as heart burn,<br>abdominal pain, nausea, vomiting, diarrhoea) |
|                      | Cutaneous use:<br>skin and subcutaneous tissue disorders   |

| Well-established use | Traditional use   |
|----------------------|---|
|                      | contact eczema<br>The frequency is not known.<br>If other adverse reactions not mentioned above<br>occur, a doctor or a qualified health care |
|                      | practitioner should be consulted.   |

#### 4.9. Overdose

| Well-established use | Traditional use  |
|----------------------|--|
|                      | Intake of doses larger than those recommended<br>can provoke gastro-intestinal symptoms (such<br>as abdominal pain, vomiting, diarrhoea,<br>nausea); respiratory problems; central nervous<br>problems (such as CNS depression, loss of<br>consciousness, convulsions, ataxia), constricted<br>pupils. |
|                      | Accidental overdose of liniments or bath preparations may cause skin irritation.   |

# 5. Pharmacological properties

#### 5.1. Pharmacodynamic properties

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC. |

#### 5.2. Pharmacokinetic properties

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC. |

#### 5.3. Preclinical safety data

| Well-established use | Traditional use   |
|----------------------|---|
|                      | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC, unless necessary for the safe use of the product. |

| Well-established use | Traditional use  |
|----------------------|--|
|                      | Adequate tests on reproductive toxicity,<br>genotoxicity and carcinogenicity have not been<br>performed. |

# 6. Pharmaceutical particulars

| Well-established use | Traditional use |
|----------------------|-----------------|
|                      | Not applicable. |

# 7. Date of compilation/last revision

20 March 2024